Search

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…

Read more

All-encompassing meeting on ALL highly rated by participants

Almost 200 delegates from over 30 countries benefitted from stimulating and excellent discussions about Acute Lymphoblastic Leukemia (ALL) at the EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia on April 12-14, 2018 in…

Read more

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy

The EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy brought together basic science, as well as translational and clinical research on November 23-25, 2017 in Amsterdam, The Netherlands.

Read more

Madrid Declaration: joint call for action on training requirements

The Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive enjoyed broad support from national society representatives at the EHA22 National Societies Dinner in Madrid.

Read more

EuroBloodNet aims for better care for patients with rare blood disorders

ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.

Read more

EHA’s advocacy for hematology continues

The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:

Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…

Read more

European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Read more

New GFI1B variants in bleeding and platelet disorders

Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more